Teva launches generic Lamictal tablets in US

Teva’s Lamotrigine tablets are the AB-rated generic equivalent of GlaxoSmithKline’s Lamictal tablets, and are indicated as adjunctive therapy in the treatment of partial seizures and the generalized seizures of Lennox-Gastaut syndrome, for conversion to monotherapy in adults with partial seizures who are taking certain other antiepileptic agents, and for maintenance treatment of bipolar I disorder.

Previously GlaxoSmithKline and Teva entered into an agreement to settle patent litigation under which GlaxoSmithKline granted Teva the exclusive right to manufacture and sell a generic version of Lamictal during the six-month pediatric exclusivity which ends on January 22, 2009.